7087-60-7

Usage

Uses

Used in Pharmaceutical Synthesis:
1-fluoro-3-methoxy-5-nitrobenzene is used as a key intermediate for the production of various pharmaceuticals, contributing to the development of new drugs with specific therapeutic properties. Its presence in the molecular structure can influence the pharmacokinetics and pharmacodynamics of the resulting compounds.
Used in Agrochemical Production:
In the agrochemical industry, 1-fluoro-3-methoxy-5-nitrobenzene is utilized as a precursor in the synthesis of pesticides and other crop protection agents. Its incorporation can enhance the effectiveness of these products, potentially leading to improved agricultural yields and pest control.
Used in Organic Chemistry Research:
As a building block in organic chemistry, 1-fluoro-3-methoxy-5-nitrobenzene is employed in academic and industrial research settings. It is used to explore novel chemical reactions and to develop new synthetic methodologies, broadening the scope of organic synthesis.
Safety Considerations:
Given its potential health hazards, including being a skin and eye irritant and possibly causing respiratory irritation, 1-fluoro-3-methoxy-5-nitrobenzene requires careful handling with appropriate protective equipment to ensure the safety of those working with the compound.

InChI:InChI=1/C7H6FNO3/c1-12-7-3-5(8)2-6(4-7)9(10)11/h2-4H,1H3

Upstream product

• 2369-10-0 3-fluoro-5-nitrophenol 
• 77-78-1 dimethyl sulfate 
• 67-56-1 methanol 
• 2265-94-3 1,3-difluoro-5-nitrobenzene 
• 586-10-7 3-methoxy-5-nitroaniline 
• 110-46-3 isopentyl nitrite 

Downstream Products

• 93398-05-1 4-(3-methoxy-5-nitrophenyl)morpholine 
• 939771-60-5 3-fluoro-5-iodophenol 
• 1167056-58-7 1-fluoro-3-iodo-5-methoxybenzene 
• 1333950-17-6 C₂₃H₁₆FN₅O 
• 1352622-33-3 C₁₆H₁₀FN₃O 
• 2339-58-4 3-fluoro-5-methoxyphenylamine 
• 2369-10-0 3-fluoro-5-nitrophenol 
• 16147-07-2 1,3-dimethoxy-5-nitrobenzene 

Relevant academic research and scientific papers

Novel pazopanib derivatives and pharmaceutical composition comprising the same

The present invention relates to novel pazopanib derivatives or a salt thereof having inhibition activities of angiogenesis and epidermal growth factors at the same time, and to a pharmaceutical composition comprising the same as an active ingredient. The pazopanib derivatives have inhibition activities of angiogenesis and epidermal growth factors at the same time unlike pazopanib, thereby more effectively treating and preventing EGFR-related cancer diseases such as lung cancer, colon cancer or breast cancer through a multiple aim target, and effectively treating and preventing non-small-cell lung cancer which Iressa or Tarceva cannot have an effect on.COPYRIGHT KIPO 2017

Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) that interfere with the replication of human immunodeficiency virus (HIV) are being pursued with guidance from molecular modeling including free-energy perturbation (FEP) calculations for protein-in

Development of CXCR3 antagonists. Part 4: Discovery of 2-amino-(4-tropinyl)quinolines

The synthesis and biological evaluation of a novel series of 2-aminoquinoline substituted piperidines and tropanes incorporating a homotropene moiety is herein described. The series exhibits potent antagonism of the CXCR3 receptor and superior physicochem

Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists

The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.